FAM131C Inhibitors
FAM131C inhibitors encompass a diverse array of chemical compounds, each targeting specific signaling pathways that lead to the diminished functional activity of FAM131C. For instance, PD 0332991, by inhibiting CDK4/6, prevents cell cycle progression and phosphorylation of Rb, which could indirectly result in reduced FAM131C activity associated with cell proliferation. Similarly, LY 294002, as a PI3K inhibitor, and Rapamycin, as an mTOR inhibitor, disrupt critical signaling pathways necessary for cellular growth and survival, thereby potentially diminishing the role of FAM131C in these processes. Trametinib, by blocking MAPK/ERK signaling, and Bortezomib, through proteasome inhibition, can lead to decreased cell proliferation and increased apoptosis, respectively. Suberoylanilide Hydroxamic Acid changes gene expression patterns by inhibiting HDAC, and Nutlin-3 antagonizes MDM2 to stabilize p53, both leading to cell cycle arrest and apoptosis.
The functional contribution of FAM131C activity is also targeted by compounds such as PI-103, a dual PI3K/mTOR inhibitor, and AZD8055, an ATP-competitive inhibitor of mTOR that impedes both mTORC1 and mTORC2 complexes. Moreover, Dasatinib, with its broad action on tyrosine kinases including BCR-ABL and Src family kinases, may reduce FAM131C activity by curtailing proliferative and survival signaling. Staurosporine, known for its wide-ranging kinase inhibition, could similarly result in the downregulation of FAM131C by inducing apoptosis across various cell types. Lastly, Olaparib, a PARP inhibitor, enhances DNA damage and cell death, potentially decreasing FAM131C's involvement in DNA repair mechanisms and cancer cell survival. Collectively, these FAM131C inhibitors target the protein indirectly by attenuating the signaling cascades and cellular processes in which it is involved, thereby reducing its functional activity within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
A CDK4/6 inhibitor that impedes cell cycle progression by preventing Rb phosphorylation, which can lead to cell cycle arrest. As FAM131C is involved in cell proliferation and cancer metastasis, inhibiting CDK4/6 can indirectly diminish FAM131C's role in these processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that blocks the PI3K/AKT signaling pathway. FAM131C, being associated with tumorigenic activities, may have its functions indirectly diminished due to reduced AKT activation and subsequent downstream effects on cell survival and proliferation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that disrupts the mTORC1 pathway, which is involved in cell growth and proliferation. By inhibiting mTOR, Rapamycin can indirectly diminish FAM131C's contributions to cell growth, particularly in cancer cells. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
A MEK inhibitor that blocks the MAPK/ERK pathway. As FAM131C is implicated in cancer progression, inhibiting MEK could lead to reduced ERK activation and therefore indirectly diminish FAM131C's role in cell proliferation and migration. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that leads to the accumulation of misfolded proteins and induces apoptosis in cancer cells. FAM131C, which may support cancer cell survival, could be indirectly inhibited due to the pro-apoptotic effects of Bortezomib. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
An HDAC inhibitor that alters gene expression and can induce cell cycle arrest, differentiation, and apoptosis. FAM131C, associated with oncogenic processes, could be indirectly diminished as Suberoylanilide Hydroxamic Acid modulates the acetylation status of histones and other proteins. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
An MDM2 antagonist that stabilizes p53, leading to cell cycle arrest and apoptosis in p53-wildtype cancer cells. FAM131C's role in cell proliferation could be indirectly diminished as Nutlin-3 enhances p53 activity, opposing the proliferative signals. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
A dual PI3K/mTOR inhibitor that leads to reduced AKT phosphorylation and mTOR signaling, thereby inhibiting cell growth and survival. The inhibition of these pathways can indirectly diminish the role of FAM131C in cancer cell proliferation and survival. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
An ATP-competitive inhibitor of mTOR that blocks both mTORC1 and mTORC2 complexes, leading to decreased cell growth and angiogenesis. This could indirectly diminish the role of FAM131C in promoting oncogenic processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A tyrosine kinase inhibitor that targets BCR-ABL and Src family kinases, inhibiting multiple oncogenic signaling pathways. FAM131C, which may play a role in oncogenesis, could be indirectly diminished by the broad inhibition of these kinases. | ||||||